Immediate results of micropulse cyclophotocoagulation in glaucoma in children

Abstract

AIM: This study aimed to investigate the efficacy and safety of micropulse cyclophotocoagulation (MP-CPC) in the treatment of various types of glaucoma in children.
 MATERIAL AND METHODS: The study included 14 children (15 eyes) with uncompensated glaucoma of various etiologies, who underwent MP-CPC using the Cyclo G6 laser system (IRIDEX, USA). The intervention was considered absolutely effective when IOP reached 8 to 25 mm Hg without medications and without signs of progression of glaucoma, relatively effective, when the same criteria are achieved with hypotensive medications.
 RESULTS: The average age of children at the time of intervention was 8.51.5 yr (from 7 months to 17 yr). The average level of IOP before surgery was 28.51.1 mm Hg, 3 days after MP-CPC (18.871.04 mm Hg), while the absolute efficiency was 14.3%, relative 100%. By the end of the observation period (16 months; on average, 2.50.4 months), the average IOP was 24.41.31 mm Hg (average decrease, 14.3%), with absolute efficiency of 0% and relative of 66.7%. The average number of hypotensive medications received in instillations did not change significantly before and after MP-CPC and amounted to 3.450.22 and 2.910.39, respectively (p=0.167). Complications after MP-CPC were detected in six eyes (40%); in all cases, the appearance or increase of the inflammatory reaction in the anterior chamber was observed. In addition, in two eyes (13.3%). In addition, a slight mydriasis (45 mm) developed.
 CONCLUSION: MP-CPC is a safe and effective treatment for glaucoma in children with various etiologies. Further research is needed to evaluate the effectiveness of intervention in the long term and the safety of repeated procedures to achieve normal IOP and to develop individual schemes of MP-CPC.

Efficacy of micropulse cyclophotocoagulation in acute angle-closure glaucoma

“…Данная технология может применяться при различных формах и стадиях глаукомы. Многочисленные российские и зарубежные публикации свидетельствуют об эффективности и безопасности применения мЦФК при первичной открытоугольной глаукоме I-III стадии, вторичной, врождённой глаукоме [25][26][27][28][29][30].…”